Related Experiment Video

Updated: May 3, 2026

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

8.0K

ABCG2 gene amplification and expression in esophageal cancer cells with acquired adriamycin resistance

Liang Liu1, Lian Fu Zuo1, Jian Wen Guo1

  • 1Department of Flow Cytometry Analysis, Tumor Institute, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei 050011, P.R. China.

Molecular Medicine Reports
|February 19, 2014
PubMed

Insights

Multidrug resistance (MDR) in esophageal cancer is linked to increased expression of ATP-binding cassette transporter G2 (ABCG2). This study found higher ABCG2 levels and drug efflux in resistant cells, suggesting ABCG2

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Chemotherapeutic resistance is a major cause of cancer treatment failure.
  • Multidrug resistance (MDR) is often mediated by drug efflux transporters like ATP-binding cassette transporter G2 (ABCG2).
  • Mechanisms of MDR in esophageal cancer remain largely undescribed.

Purpose of the Study:

  • To investigate the role of ABCG2 in adriamycin (ADM)-resistant esophageal cancer cells.
  • To characterize the adriamycin-resistant esophageal cancer subline Eca109/ADM.
  • To determine the correlation between ABCG2 expression and MDR in esophageal cancer.

Main Methods:

  • Generation of an adriamycin-resistant esophageal cancer cell line (Eca109/ADM) through stepwise selection.
  • Assessment of ADM resistance fold-change compared to the parental cell line.
  • Detection of ABCG2 gene and protein expression using RT-PCR, flow cytometry, and western blotting.
  • Evaluation of drug efflux effects via flow cytometry.

Main Results:

  • The Eca109/ADM subline exhibited a 3.29-fold increase in resistance to ADM.
  • ABCG2 gene and protein expression levels were significantly elevated in Eca109/ADM cells compared to Eca109 cells.
  • Increased drug efflux was observed in the Eca109/ADM cells, correlating with higher ABCG2 expression.

Conclusions:

  • Overexpression of ABCG2 in esophageal cancer cells contributes to adriamycin resistance.
  • Elevated ABCG2 levels facilitate drug efflux, playing a key role in the development of esophageal cancer MDR.
  • These findings highlight ABCG2 as a potential therapeutic target for overcoming MDR in esophageal cancer.

More Related Videos

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

7.6K
Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

6.5K

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.3K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
81
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
2.6K
Barrett Esophagus-I: Introduction01:21

Barrett Esophagus-I: Introduction

Barrett's esophagus is a medical condition where the esophageal mucosa is significantly damaged by stomach acid or other digestive fluids, often due to long-term exposure associated with gastroesophageal reflux disease (GERD). In GERD, a weakened or abnormally relaxed lower esophageal sphincter allows stomach acid to flow persistently into the esophagus.
This constant acid exposure transforms the esophagus's pink mucosal lining (stratified squamous epithelium) into a type of lining more...
1.5K